News stories about Editas Medicine (NASDAQ:EDIT) have trended somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Editas Medicine earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 44.4915338252895 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Editas Medicine Inc (EDIT) Expected to Announce Quarterly Sales of $3.33 Million (americanbankingnews.com)
- Brokerages Expect Editas Medicine Inc (EDIT) to Post -$0.79 EPS (americanbankingnews.com)
- Editas Medicine, Inc. (NASDAQ:EDIT) – Hot Stock in the Spotlight – Nasdaq Journal (press release) (nasdaqjournal.com)
- 3. Why buy CRISPR Therapeutics and not the others? – Motley Fool (fool.com)
- Editas Medicine Joins Elite Club Of Stocks With RS Ratings Over 90 … – Investor’s Business Daily (investors.com)
A number of research analysts have recently weighed in on EDIT shares. ValuEngine cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. Zacks Investment Research cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Cann reissued a “hold” rating on shares of Editas Medicine in a research note on Tuesday, November 7th. Morgan Stanley reissued an “equal weight” rating and set a $28.00 price objective (up from $27.00) on shares of Editas Medicine in a research note on Friday, October 6th. Finally, BidaskClub cut shares of Editas Medicine from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $26.73.
Editas Medicine (NASDAQ:EDIT) last released its earnings results on Tuesday, November 7th. The company reported ($0.64) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.04). The firm had revenue of $6.28 million during the quarter, compared to analysts’ expectations of $2.66 million. Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The firm’s revenue was up 553.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.59) earnings per share. equities analysts anticipate that Editas Medicine will post -2.92 earnings per share for the current fiscal year.
In other news, insider Katrine Bosley sold 8,333 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $23.64, for a total transaction of $196,992.12. Following the completion of the sale, the insider now directly owns 1,393,322 shares of the company’s stock, valued at approximately $32,938,132.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew A. F. Hack sold 5,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $24.31, for a total transaction of $121,550.00. Following the sale, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at $121,550. The disclosure for this sale can be found here. Insiders sold a total of 54,648 shares of company stock valued at $1,383,861 over the last ninety days. 19.40% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Editas Medicine (EDIT) Share Price” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.com-unik.info/2017/12/27/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-editas-medicine-edit-share-price.html.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
What are top analysts saying about Editas Medicine? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Editas Medicine and related companies.